Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, +239

The Lancet

Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment +4

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod, Maen Hussein, +17

The Lancet Oncology

MedicineMetronomic TherapyPharmacologyPathologyBronchial Neoplasm +7

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, +247

The Lancet Oncology

Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment +4

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín, +18

Journal of Thoracic Oncology

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Amir Massarweh, Noa Eliakim‐Raz, Amos Stemmer, +12

JAMA Oncology

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, +16

Journal of Thoracic Oncology

Tumor Mutational BurdenDeath Ligand 1MedicineImmunologyCancer Genomics +7

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Hyun Cheol Chung, José A. López-Martín, Stephen Chuan-Hao Kao, +13

Journal of Clinical Oncology

Sclc PtsImmunologyImmunoeditingImmunotherapeuticsImmunotherapy +14

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Mrinal M. Gounder, Alona Zer, William D. Tap, +22

Journal of Clinical Oncology

Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer

Alona Zer, Mike Sung, Preet Walia, +11

Clinical Lung Cancer

Pd-1 Axis InhibitorsCancer ImmunosurveillanceAdvanced Lung DiseaseMedicineAbsolute Neutrophil Count +8

Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases

Elizabeth Dudnik, Shlomit Yust‐Katz, Hovav Nechushtan, +5

Lung Cancer

Neuro-oncologyCns MetastasesIntracranial PressureNeuroimagingNeurology +6